Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: Two-year results including pharmacokinetics and concomitant hydroxyurea

American Journal of Hematology

Volumn 88, Issue 12, 2013, Pages 1068-1073

  Vichinsky, Elliott ^a   Torres, Marcela ^b   Minniti, Caterina P ^c   Barrette, Stephane ^d   Habr, Dany ^e   Zhang, Yiyun ^e   Files, Beatrice ^f  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b Cook Childrens Hospital ^*  (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d UNIVERSITY OF MONTREAL   (Canada)

^e NOVARTIS PHARMA AG   (Switzerland)

^f EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFEROXAMINE; FERRITIN; HYDROXYUREA;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; CHILD; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL DISEASE; HUMAN; INJECTION SITE IRRITATION; INJECTION SITE PAIN; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SICKLE CELL ANEMIA; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ACUTE KIDNEY INJURY; ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; BENZOATES; BLOOD TRANSFUSION; CELLULITIS; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; DEFEROXAMINE; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; FEMALE; FERRITINS; HUMANS; HYDROXYUREA; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TRIAZOLES; YOUNG ADULT;

EID: 84888039064     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23569     Document Type: Article

References (24)

1. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5-11.
2. Vichinsky E, Butensky E, Fung E, et al. Comparison of organ dysfunction in transfused patients with SCD or β thalassemia. Am J Hematol 2005;80:70-74.
3. Vichinsky E, Onyekwere O, Porter J, et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007;136:501-508.
4. Vichinsky E, Bernaudin F, Forni GL, et al. Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol 2011;154:387-397.
5. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). Lancet 2011;377:1663-1672.
6. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332:1317-1322.
7. Olivieri NF, Vichinsky EP. Hydroxyurea in children with sickle cell disease: Impact on splenic function and compliance with therapy. J Pediatr Hematol Oncol 1998;20:26-31.
8. Voskaridou E, Bilalis A, Christoulas D, et al. Prolonged administration of hydroxyurea reduces morbidity and mortality in adult patients with sickle-cell syndromes: Final analysis of a 17-year, single center trial. Haematologica 2009;94(Suppl 2):Abstract 1079.
9. Alvarez O, Yovetich NA, Scott JP, et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: Results from the SWiTCH clinical trial. Am J Hematol. 2013; doi: 10.1002/ajh.23547. [Epub ahead of print].
10. Strouse JJ, Lanzkron S, Beach MC, et al. Hydroxyurea for sickle cell disease: A systematic review for efficacy and toxicity in children. Pediatrics 2008;122:1332-1342.
11. Segal JB, Strouse JJ, Beach MC, et al. Hydroxyurea for the Treatment of Sickle Cell Disease. Evidence Report/Technology Assessment No. 165. (Prepared by Johns Hopkins University Evidence-based Practice Center under contract no. 290-02-0018). AHRQ Publication No 08-E007 Rockville, MD Agency for Healthcare Research and Quality 2008.
12. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999;94:1550-1554.
13. Bristol-Myers Squibb. HYDREA (Hydroxyurea Capsules, USP) Prescribing Information. Princeton, NJ: Bristol-Myers Squibb; 2011.
14. II. Eur J Inorg Chem 2004;21:4177-4192.
15. Sickle Cell Society. Standards for the Clinical Care of Adults with Sickle Cell Disease in the UK. London: Sickle Cell Society; 2008. Available at: http://www.sicklecellsociety.org/app/webroot/files/files/CareBook.pdf.
16. NIH. NIH Publication No. 02-2117.Bethesda, MD: NIH; 2002.
17. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003;361:1597-1602.
18. Audard V, Homs S, Habibi A, et al. Acute kidney injury in sickle patients with painful crisis or acute chest syndrome and its relation to pulmonary hypertension. Nephrol Dial Transplant 2010;25:2524-2529.
19. Grange S, Bertrand DM, Guerrot D, et al. Acute renal failure and Fanconi syndrome due to deferasirox. Nephrol Dial Transplant 2010;25:2376-2378.
20. Rheault MN, Bechtel H, Neglia JP, Kashtan CE. Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatr Blood Cancer 2011;56:674-676.
21. Brosnahan G, Gokden N, Swaminathan S. Acute interstitial nephritis due to deferasirox: A case report. Nephrol Dial Transplant 2008;23:3356-3358.
22. Cancado R, Olivato MC, Bruniera P, et al. Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients. Acta Haematol 2012;128:113-118.
23. Vlachaki E, Mainou M, Bekiari E, et al. Safety and efficacy of 4 years of deferasirox treatment for sickle cell disease patients. Hemoglobin 2013;37:94-100.
24. Novartis Pharmaceuticals. Exjade® (deferasirox) Basic Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals; 2013. Available at: http://www.exjade.com/index.jsp.